Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $38 from $32 and keeps a Neutral rating on the shares. The strong quarter on TAVALISSE $44.7M proved that the strong uptick we saw in Q3 wasn’t a one-time fluke, the analyst tells investors in a research note. The firm thinks the pipeline opportunity deserves “equal attention” in light of the trends from TAVALISSE in 2025.